Overview of Project
The Prelapse Program is a research study that will compare two different ways of providing treatment for people experiencing the early stages of schizophrenia. The goal of this program is to show that the best possible option for preventing relapses in patients suffering from first episode (<1 year of anti-psychotic medication) or early phase (<5 years of lifetime exposure to anti-psychotic medication) schizophrenia is by enhancing medication adherence. The participating research sites (not individual patients) will be randomly assigned to either medication prescribed by their treating physician (with no restrictions) or to a regimen that involves a monthly long acting injectable antipsychotic. Patients enrolled in the study will participate in regular assessments either over the phone or in person and be followed for a period of 2 years.
Dr. John Kane from the Zucker Hillside Hospital in Glen Oak, NY is directing the Prelapse study. The study will take place in 34 community mental health centers and hospital outpatient mental health facilities in 21 states across the nation. For a complete list of the Prelapse treatment facilities see Study Locations. If you are interested in learning more about the study, please contact the Prelapse location nearest you.